Pharmaceutical Moderna announced Tuesday that its COVID-19 vaccine is effective in children ages 12 to 17, making it the second vaccine in the country available for children.
Company officials said they studied more than 3,700 people between the ages of 12 and 17 as part of a phase 2/3 trial of the vaccine. Preliminary studies indicated that the vaccine led to the same signs of immune protection in children as it did in adults, with the same kinds of temporary side effects, such as pain in the arms, head and fatigue.
